NASDAQ:XLO
Xilio Therapeutics, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.xiliotx.comipo date
Oct 22, 2021
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a m...Show More
Earnings
Earnings Release in 16 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus